论文部分内容阅读
目的:探讨罗格列酮与二甲双胍联合给药对多囊卵巢综合征(PCOS)患者胰岛素抵抗指数(HOMA-IR)的变化影响与临床效果的评价。方法:回顾性选取我院收治的PCOS患者127例列为研究样本,按照用药方案差异分为两组,对照组62例采用二甲双胍进行治疗;研究组65例采用罗格列酮联合二甲双胍治疗。观察并比较两组患者治疗前后HOMA-IR、血清性激素水平、排卵率及副反应发生情况。结果:治疗后,研究组HOMA-IR低于对照组,排卵率高于对照组(P<0.05);研究组患者血清E2及T水平低于对照组,而FSH及SHBG水平高于对照组(P<0.05);两组患者副反应发生率比较,差异无统计学意义(P>0.05)。结论:罗格列酮辅助二甲双胍治疗PCOS可显著改善患者HOMA-IR,对性激素平衡有良好作用,副作用较小。
Objective: To evaluate the effect of rosiglitazone combined with metformin on the changes of insulin resistance index (HOMA-IR) in patients with polycystic ovary syndrome (PCOS) and the clinical evaluation. Methods: A retrospective study of 127 patients with PCOS admitted to our hospital was included in the study sample. The patients were divided into two groups according to the difference in dosage regimen. Sixty-two patients in the control group were treated with metformin. Sixty-five patients in the study group were treated with rosiglitazone combined with metformin. The levels of HOMA-IR, serum sex hormones, ovulation rate and side effects before and after treatment were observed and compared between two groups. Results: After treatment, the HOMA-IR in the study group was lower than that in the control group, and the ovulation rate was higher than that in the control group (P <0.05). The levels of serum E2 and T in the study group were lower than those in the control group, while the levels of FSH and SHBG were higher P <0.05). There was no significant difference in the incidence of side effects between the two groups (P> 0.05). CONCLUSION: Rosiglitazone-assisted metformin treatment of PCOS can significantly improve HOMA-IR in patients with good sex hormone balance, with fewer side effects.